The impact of benzodiazepine use on treatment retention in opioid agonist treatment: A literature review

Abstract

It is well established that there is an elevated overdose risk with benzodiazepine (BZD) use during opioid agonist treatment (OAT). However, further studies regarding other aspects of how BZDs influence OAT are necessary. This review summarizes the literature on concurrent BZD use with medications for opioid use disorder (MOUD) and how they affect treatment retention in OAT. EMBASE (Ovid), PubMed, and Google Scholar database search tools were used to search for studies that examined the effect of concurrent BZD and MOUD on treatment retention in OAT. Studies published up to January 30th, 2024, were included with no restriction applied other than English language. The criteria for included literature were the presence of both BZD and at least one MOUD as a variable and treatment retention or MOUD adherence as an outcome. Fourteen articles met the criteria for review: eleven retrospective studies and three observational studies. Methadone was utilized in seven studies, buprenorphine in five, naltrexone in one, and suboxone (buprenorphine + naloxone) in one study. The included studies indicated that when BZDs are taken as prescribed and for shorter periods in conjunction with OAT, subjects are retained in their MOUD programs just as well as patients who do not take BZDs. Any potential benefits of increased treatment retention must be balanced against potential harmful effects of BZD use, such as drug overdose and addiction. Further studies must be performed to validate the results of treatment retention and to evaluate other factors that might affect OAT.

Keywords

Benzodiazepine / Opioid agonist therapy / Treatment retention

Funding

The present review was supported in part by a NSERC Discovery grant to AMB.

Conflict of interest

The authors declare they have no competing interests.

References

[1] Compton P. The United States opioid crisis: Big pharma alone is not to blame. Prev Med. 2023;177:107777. doi: 10.1016/j.ypmed.2023.107777

[2] Judd D, King CR, Galke C. The opioid epidemic: A review of the contributing factors, negative consequences, and best practices. Cureus. 2023; 15(7):e41621. doi: 10.7759/cureus.41621

[3] Cuadros DF, Branscum AJ, Moreno CM, MacKinnon NJ. Narrative minireview of the spatial epidemiology of substance use disorder in the United States: Who is at risk and where? World J Clin Cases. 2023; 11(11):2374-2385. doi: 10.12998/wjcc.v11.i11.2374

[4] Jones AA, Jang K, Panenka WJ, et al. Rapid change in fentanyl prevalence in a community-based, high-risk sample. JAMA Psychiatry. 2018; 75(3):298-300. doi: 10.1001/jamapsychiatry.2017.4432

[5] Jones AA, Vila-Rodriguez F, Leonova O, et al. Mortality from treatable illnesses in marginally housed adults: A prospective cohort study. BMJ Open. 2015; 5(8):e008876. doi: 10.1136/bmjopen-2015-008876

[6] Krausz RM, Westenberg JN, Ziafat K. The opioid overdose crisis as a global health challenge. Curr Opin Psychiatry. 2021; 34:405-412. doi: 10.1097/yco.0000000000000712

[7] Okoli CT, Khara M, Procyshyn RM, Johnson JL, Barr AM, Greaves L. Smoking cessation interventions among individuals in methadone maintenance: A brief review. J Subst Abuse Treat. 2010; 38(2):191-199. doi: 10.1016/j.jsat.2009.10.001

[8] Santo T Jr., Gisev N, Campbell G, et al. Prevalence of comorbid substance use disorders among people with opioid use disorder: A systematic review and meta-analysis. Int J Drug Policy. 2024;128:104434. doi: 10.1016/j.drugpo.2024.104434

[9] Ellis JD, Dunn KE, Huhn AS. Harm reduction for opioid use disorder: Strategies and outcome metrics. Am J Psychiatry. 2024; 181(5):372-380. doi: 10.1176/appi.ajp.20230918

[10] Mannaioni G, Lugoboni F. Precautions in the management of opioid agonist therapy: From target population characteristics to new formulations and post-marketing monitoring - a focus on the Italian system. Drugs Context. 2023; 12:1-9. doi: 10.7573/dic.2023-2-6

[11] Mendell A, Vannabouathong C, Le K, Dyrda P. Utilization of Opioid Agonist Therapies in Canada: CADTH Health Technology Review. Ottawa, ON: Canadian Agency for Drugs and Technologies in Health; 2023.

[12] Sugarman A, Vittitow A, Cheng A, et al. Opioid use disorder treatments: An evidence map. Drug Alcohol Depend. 2022;241:109657. doi: 10.1016/j.drugalcdep.2022.109657

[13] White KM, Hill LG, Perez JC, Torrez SB, Zagorski CM, Loera LJ. Policies regarding use of medications for opioid use disorder in professional recovery programs: A scoping review. Subst Abuse. 2022; 43(1):749-755. doi: 10.1080/08897077.2021.2010161

[14] Torres-Lockhart KE, Lu TY, Weimer MB, Stein MR, Cunningham CO. Clinical management of opioid withdrawal. Addiction. 2022; 117(9):2540-2550. doi: 10.1111/add.15818

[15] Carswell N, Angermaier G, Castaneda C, Delgado F. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting. Hospital Pract (1995). 2022; 50(4):251-258. doi: 10.1080/21548331.2022.2102776

[16] Taylor JL, Wakeman SE, Walley AY, Kehoe LG. Substance use disorder bridge clinics: Models, evidence, and future directions. Addict Sci Clin Pract. 2023; 18(1):23. doi: 10.1186/s13722-023-00365-2

[17] Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373:n784. doi: 10.1136/bmj.n784

[18] Schmitz A. Benzodiazepine use, misuse, and abuse: A review. Ment Health Clin. 2016; 6(3):120-126. doi: 10.9740/mhc.2016.05.120

[19] Bakouni H, Sharafi H, Drouin S, et al. Associations between buprenorphine\naloxone and methadone treatment and non-opioid substance use in prescription-type opioid use disorder: Secondary analyses from the OPTIMA Study: Associations entre le traitement avec la buprénorphine/ naloxone et avec la méthadone et l’utilisation de substances non opioïdes dans le trouble lié à l’usage d’opioïdes de type sur ordonnance: Analyses secondaires de l’étude OPTIMA. Can J Psychiatry. 2024; 69(4):252-263. doi: 10.1177/07067437231210796

[20] Mahu IT, Conrod PJ, Barrett SP, Sako A, Swansburg J, Stewart SH. The four-factor personality model and its qualitative correlates among opioid agonist therapy clients. Front Psychiatry. 2023;14:1129274. doi: 10.3389/fpsyt.2023.1129274

[21] Lei M, Rintoul K, Stubbs JL, et al. Characterization of bodily pain and use of both prescription and non-prescription opioids in tenants of precarious housing. Subst Use Misuse. 2021; 56(13):1951-1961. doi: 10.1080/10826084.2021.1958865

[22] Greenblatt DJ, Shader RI, Abernethy DR. Drug therapy. Current status of benzodiazepines. N Engl J Med. 1983; 309(7):410-416. doi: 10.1056/nejm198308183090705

[23] Sanabria E, Cuenca RE, Esteso M, Maldonado M. Benzodiazepines: Their use either as essential medicines or as toxics substances. Toxics. 2021; 9(2):25. doi: 10.3390/toxics9020025

[24] Jones JD, Mogali S, Comer SD. Polydrug abuse: A review of opioid and benzodiazepine combination use. Drug Alcohol Depend. 2012; 125(1-2):8-18. doi: 10.1016/j.drugalcdep.2012.07.004

[25] Bharat C, Gisev N, Barbieri S, et al. Prescription opioid use among people with opioid dependence and concurrent benzodiazepine and gabapentinoid exposure: An analysis of overdose and all-cause mortality. Int J Drug Policy. 2024;123:104287. doi: 10.1016/j.drugpo.2023.104287

[26] Macleod J, Steer C, Tilling K, et al. Prescription of benzodiazepines, z-drugs, and gabapentinoids and mortality risk in people receiving opioid agonist treatment: Observational study based on the UK Clinical Practice Research Datalink and Office for National Statistics death records. PLoS Med. 2019; 16(11):e1002965. doi: 10.1371/journal.pmed.1002965

[27] Olopoenia A, Camelo-Castillo W, Qato DM, et al. Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: A nested case-control study. Lancet Reg Health Am. 2022;13:100302. doi: 10.1016/j.lana.2022.100302

[28] DeHaan M, Radtke L, Hensley C, Hogue A. Determining efficacy of intervention in the limitation of opioid and benzodiazepine co-prescription. S D Med. 2020; 73(10):480-483.

[29] Russell C, Law J, Bonn M, Rehm J, Ali F. The increase in benzodiazepine-laced drugs and related risks in Canada: The urgent need for effective and sustainable solutions. Int J Drug Policy. 2023;111:103933. doi: 10.1016/j.drugpo.2022.103933

[30] Andersen PA, Thomsen AH, Hasselstrøm JB, et al. Exploring death scenes and circumstances in fatal opioid poisonings: Insights for preventive strategies using forensic autopsy cases in Western Denmark. Forensic Sci Int. 2024;356:111948. doi: 10.1016/j.forsciint.2024.111948

[31] Park TW, Saitz R, Ganoczy D, Ilgen MA, Bohnert AS. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: Case-cohort study. BMJ. 2015;350:h2698. doi: 10.1136/bmj.h2698

[32] U.S. Food and Drug Administration. FDA Drug Safety Communication: FDA Urges Caution about Withholding Opioid Addiction Medications from Patients Taking Benzodiazepines or CNS Depressants: Careful Medication Management Can Reduce Risks. United States: U.S. Food and Drug Administration; 2017.

[33] Eadie L, Lo LA, Christiansen A, et al. Duration of neurocognitive impairment with medical cannabis use: A scoping review. Front Psychiatry. 2021; 12(286):638962. doi: 10.3389/fpsyt.2021.638962

[34] MacCallum CA, Eadie L, Barr AM, Boivin M, Lu S. Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain. Front Pharmacol. 2021; 12(907):633168. doi: 10.3389/fphar.2021.633168

[35] Tse L, Procyshyn RM, Fredrikson DH, Boyda HN, Honer WG, Barr AM. Pharmacological treatment of antipsychotic-induced dyslipidemia and hypertension. Int Clin Psychopharmacol. 2014; 29(3):125-137. doi: 10.1097/YIC.0000000000000014

[36] Whitney Z, Procyshyn RM, Fredrikson DH, Barr AM. Treatment of clozapine-associated weight gain: A systematic review. Eur J Clin Pharmacol. 2015; 71(4):389-401. doi: 10.1007/s00228-015-1807-1

[37] Yuen JWY, Kim DD, Procyshyn RM, Panenka WJ, Honer WG, Barr AM. A focused review of the metabolic side-effects of clozapine. Front Endocrinol (Lausanne). 2021;12:609240. doi: 10.3389/fendo.2021.609240

[38] Ray-Griffith S, Tharp E, Coker JL, Catlin D, Knight B, Stowe ZN. Buprenorphine medication for opioid use disorder: A study of factors associated with postpartum treatment retention. Am J Addict. 2021; 30(1):43-48. doi: 10.1111/ajad.13084

[39] Morford KL, Tetrault JM, Zhou B, et al. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug Alcohol Depend. 2022;241:109707. doi: 10.1016/j.drugalcdep.2022.109707

[40] Brands B, Blake J, Marsh DC, Sproule B, Jeyapalan R, Li S. The impact of benzodiazepine use on methadone maintenance treatment outcomes. J Addict Dis. 2008; 27(3):37-48. doi: 10.1080/10550880802122620

[41] Durand L, Boland F, O’Driscoll D, et al. Factors associated with early and later dropout from methadone maintenance treatment in specialist addiction clinics: A six-year cohort study using proportional hazards frailty models for recurrent treatment episodes. Drug Alcohol Depend. 2021;219:108466. doi: 10.1016/j.drugalcdep.2020.108466

[42] Franklyn AM, Eibl JK, Gauthier G, Pellegrini D, Lightfoot NE, Marsh DC. The impact of benzodiazepine use in patients enrolled in opioid agonist therapy in Northern and rural Ontario. Harm Reduct J. 2017; 14(1):6. doi: 10.1186/s12954-017-0134-5

[43] Dayal P, Balhara YPS, Mishra AK. An open label naturalistic study of predictors of retention and compliance to naltrexone maintenance treatment among patients with opioid dependence. J Subst Use. 2016; 21(3):309-316. doi: 10.3109/14659891.2015.1021867

[44] Hallowell BD, Chambers LC, Samuels EA, et al. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population. Drug Alcohol Depend. 2022;241:109680. doi: 10.1016/j.drugalcdep.2022.109680

[45] Schuman-Olivier Z, Hoeppner BB, Weiss RD, Borodovsky J, Shaffer HJ, Albanese MJ. Benzodiazepine use during buprenorphine treatment for opioid dependence: Clinical and safety outcomes. Drug Alcohol Depend. 2013; 132(3):580-586. doi: 10.1016/j.drugalcdep.2013.04.006

[46] Park TW, Larochelle MR, Saitz R, Wang N, Bernson D, Walley AY. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine. Addiction. 2020; 115(5):924-932. doi: 10.1111/add.14886

[47] Raffa JD, Grebely J, Tossonian H, et al. The impact of ongoing illicit drug use on methadone adherence in illicit drug users receiving treatment for HIV in a directly observed therapy program. Drug Alcohol Depend. 2007; 89(2-3):306-309. doi: 10.1016/j.drugalcdep.2007.02.007

[48] White WL, Campbell MD, Spencer RD, Hoffman HA, Crissman B, DuPont RL. Patterns of abstinence or continued drug use among methadone maintenance patients and their relation to treatment retention. J Psychoactive Drugs. 2014; 46(2):114-122. doi: 10.1080/02791072.2014.901587

[49] Eibl JK, Wilton AS, Franklyn AM, Kurdyak P, Marsh DC. Evaluating the Impact of prescribed versus nonprescribed benzodiazepine use in methadone maintenance therapy: Results from a population-based retrospective cohort study. J Addict Med. 2019; 13(3):182-187. doi: 10.1097/adm.0000000000000476

[50] Peles E, Adelson M, Schreiber S. Benzodiazepine usage during 19.5 years in methadone maintenance treatment patients and its relation to long-term outcome. Isr J Psychiatry Relat Sci. 2014; 51(4):285-288.

[51] Montalvo C, Stankiewicz B, Brochier A, Henderson DC, Borba CPC. Long-term retention in an outpatient behavioral health clinic with buprenorphine. Am J Addict. 2019; 28(5):339-346. doi: 10.1111/ajad.12896

[52] Taha SA, Westra JR, Tacker DH, Raji MA, Kuo YF. Trends in co-prescribed opioids and benzodiazepines, non-prescribed opioids and benzodiazepines, and schedule-I drugs in the United States, 2013 to 2019. Prev Med Rep. 2024;38:102584. doi: 10.1016/j.pmedr.2023.102584

[53] Hutchison RW, Carhart J. Opioid and benzodiazepine utilization patterns in metropolitan and rural Texas. J Opioid Manag. 2023; 19(5):433-443. doi: 10.5055/jom.0817

[54] Barr AM, Panenka WJ, Honer WG, Khara S, Procyshyn RM. Excessive antipsychotic dosing in a Canadian outpatient population. Psychiatr Serv. 2011; 62(6):682-683. doi: 10.1176/ps.62.6.pss6206_0682a

[55] Jones AA, Gicas KM, Seyedin S, et al. Associations of substance use, psychosis, and mortality among people living in precarious housing or homelessness: A longitudinal, community-based study in Vancouver, Canada. PLoS Med. 2020; 17(7):e1003172. doi: 10.1371/journal.pmed.1003172

[56] Rintoul K, Song E, McLellan-Carich R, Schjelderup ENR, Barr AM. A scoping review of psychiatric conditions associated with chronic pain in the homeless and marginally housed population. Front Pain Res (Lausanne). 2023;4:1020038. doi: 10.3389/fpain.2023.1020038

[57] Troberg K, Bråbäck M, Isendahl P, Nilsson S, Dahlman D, Håkansson A. Malmö Treatment Referral and Intervention Study (MATRIS)-36-month follow-up on retention and substance use among patients referred from needle exchange to opioid agonist treatment-The role of stimulant use at baseline. J Subst Use Addict Treat. 2023;151:209036. doi: 10.1016/j.josat.2023.209036

[58] Mahu IT, Barrett SP, Conrod PJ, Bartel SJ, Stewart SH. Different drugs come with different motives: Examining motives for substance use among people who engage in polysubstance use undergoing methadone maintenance therapy (MMT). Drug Alcohol Depend. 2021;229(Pt B):109133. doi: 10.1016/j.drugalcdep.2021.109133

[59] Lintzeris N, Nielsen S. Benzodiazepines, methadone and buprenorphine: Interactions and clinical management. Am J Addict. 2010; 19(1):59-72. doi: 10.1111/j.1521-0391.2009.00007.x

[60] Brunetti P, Giorgetti R, Tagliabracci A, Huestis MA, Busardò FP. Designer benzodiazepines: A review of toxicology and public health risks. Pharmaceuticals (Basel). 2021; 14(6):560. doi: 10.3390/ph14060560

[61] Engin E. GABAA receptor subtypes and benzodiazepine use, misuse, and abuse. Front Psychiatry. 2022;13:1060949. doi: 10.3389/fpsyt.2022.1060949

[62] Jones AA, Cho LL, Kim DD, et al. Pain opioid use, depressive symptoms, and mortality in adults living in precarious housing or homelessness: A longitudinal prospective study. Pain. 2022; 163:2213-2223. doi: 10.1097/j.pain.0000000000002619

[63] Zacny JP, Paice JA, Coalson DW. Separate and combined psychopharmacological effects of alprazolam and oxycodone in healthy volunteers. Drug Alcohol Depend. 2012; 124(3):274-282. doi: 10.1016/j.drugalcdep.2012.01.023

[64] Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019; 197:78-82. doi: 10.1016/j.drugalcdep.2018.12.030

[65] Day C. Benzodiazepines in combination with opioid pain relievers or alcohol:Greater risk of more serious ED visit outcomes. In: The CBHSQ Report Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2013. p. 1-9.

[66] Gudin JA, Mogali S, Jones JD, Comer SD. Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use. Postgrad Med. 2013; 125(4):115-130. doi: 10.3810/pgm.2013.07.2684

[67] Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L. A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse. 2009; 35(1):28-33. doi: 10.1080/00952990802342899

[68] Chambers LC, Hallowell BD, Zullo AR, et al. Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl. JAMA Netw Open. 2023; 6(9):e2334540. doi: 10.1001/jamanetworkopen.2023.34540

[69] Klimas J, Hamilton MA, Gorfinkel L, Adam A, Cullen W, Wood E. Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials. Syst Rev. 2021; 10(1):216. doi: 10.1186/s13643-021-01764-9